The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

Esta hoja de hechos ofrece informacion a los pacientes sobre la buprenorfina y los tratamientos con ayuda de medicamentos para tratar el trastorno por uso de opioides, y tambien describe el mal uso y los sintomas del sindrome de abstinencia. Explica como funciona la buprenorfina, su uso apropiado, sus efectos secundarios y como se la utiliza en conjunto con al consejeria en el proceso de recuperacion.